Objective To investigate the pregnancy outcomes in a cohort of women who failed to obtain a result in non-invasive prenatal testing (NIPT).
Introduction
Cell-free fetal DNA was first discovered in maternal plasma in 1997 by Lo et al. 1 and has since become the focus of new technologies for prenatal screening.
Non-invasive prenatal testing (NIPT) involves the analysis of cell-free DNA fragments in maternal serum samples. During pregnancy, cell-free DNA consists of maternal fragments, primarily from haematopoietic cells, and fetal fragments, released from trophoblasts during apoptosis. 1 In the original technology, these DNA fragments were all sequenced, their chromosomal origins were identified using the maternal genome as a reference and processed by counting algorithms to identify molecular imbalances. 2 The development of directed amplification and sequencing has allowed for a more targeted process. 3 Some laboratories are now returning to more complete whole genome sequencing, which can identify more complex genetic disorders including sub-chromosomal genetic disorders such as microdeletion syndromes. 2, 4, 5 In Australia, the current application of NIPT is in screening during the first trimester for the common fetal chromosome abnormalities (trisomies 21, 18 and 13, and the sex chromosome aneuploidies), often as an adjunct to combined first-trimester screening. 5 The clinical validity of NIPT as a screening tool has been demonstrated by multiple studies with reported sensitivities of 99.7, 98.2 and 99.0% for trisomies 21, 18 and 13, respectively, for a combined false-positive rate of 0.13%. [6] [7] [8] Approximately 2-3% NIPT return an inconclusive result. 9, 10 There are a number of reasons for failing to achieve a result. 8 These include logistic failures due to errors in specimen collection, transport and storage, or with laboratory processing as well as technical assay failure due to failed DNA extraction, amplification or sequencing. This latter group includes those with genomic disturbance such as maternal, placental or fetal mosaicism, malignancy 11 or other (non-reported, normalising) chromosomal abnormalities. The most common cause, however, is insufficient fetal cell-free DNA fraction. 8 Fetal fraction varies between individuals and throughout the pregnancy. There are two well-established influences on fetal fraction: gestational age being positively correlated whereas maternal weight has an inverse relationship. 12 The influence of other factors such as smoking, ethnicity and chromosomal aneuploidy is less clear. 10, 13 However, there are women with low fetal fraction whose results cannot be easily accounted for by these factors.
As the use of NIPT becomes more widespread, it is increasingly important to determine any clinical implications of NIPT failure. This study aims to explore the relationship between NIPT failure and adverse pregnancy outcome.
Methods

Study design
This was a historical cohort study.
Participants and setting
Pregnant women who undertook NIPT at a private specialist, multi-site prenatal screening service in Sydney, Australia between June 2013 and March 2016 and failed to achieve a result were included in the study. No women were excluded from the study.
Procedure
Before the NIPT, all women underwent a sonographic assessment to confirm fetal number and viability and to accurately determine gestational age. Pre-test counselling regarding the scope and limitations of NIPT was provided by genetic counsellors or fetal medicine specialists. Routine venepuncture was performed to collect the sample for NIPT.
Initially, samples were transported to Ariosa Diagnostics (San Jose, CA, USA) for analysis by Harmony TM . Harmony TM reported a test failure where samples had <4% fetal fraction or when assay disturbances or laboratory processing errors occurred. Availability of testing in Australia led to a change in NIPT provider during the study period with samples being sent to Genea (Sydney, Australia) for analysis by GeneSyteâ. Genomic disturbances, assay failure and technical causes could result in an inconclusive results with this platform, but fetal fraction was not measured in the study period, relying instead on sequencing depth and increased read numbers to maintain screening accuracy. 14 Women who failed to achieve an NIPT result were given the option of sample recollection for NIPT at no additional cost using either the original testing platform or an alternative NIPT provider, or alternatively proceeding with another prenatal screening or testing pathway. Those with repeat NIPT failures were referred to a fetal medicine specialist for counselling and given the option of definitive prenatal testing by chorionic villus sampling or amniocentesis.
Data collection
Maternal characteristics (age, weight and height) and the results of any antenatal investigations comprising the firsttrimester screening, screening for pre-eclampsia and the ultrasound examination were collated. These included the placental biomarkers [free b human chorionic gonadotrophin (fbhCG), pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF)] and maternal biophysical information [mean arterial pressure (MAP) and mean uterine artery pulsatility index (PI)]. 15 Outcome information including pregnancy complications, delivery mode, neonatal characteristics and progress, was selfreported by the study participants via telephone interview conducted after the conclusion of the pregnancy.
The following definitions were used: Preterm: delivery before 37 weeks of gestation; Small-for-gestational-age (SGA): weight less than 10th centile adjusted for gestational age; Pre-eclampsia: hypertension and coexistence of at least one of proteinuria, uteroplacental dysfunction, maternal organ dysfunction (renal insufficiency, liver involvement, neurological complications); Gestational diabetes mellitus (GDM): any of fasting plasma glucose 5.1-6.9 mmol/l, 1-hour post-75-g oral glucose load >10 mmol/l, 2-hour post-75-g oral glucose load 8.5-11 mmol/l.
Statistical analysis
Due to data availability, there were two cohorts used as comparative controls; the general Australian obstetric population using data published by the Australian government [16] [17] [18] [19] and an NIPT success cohort from the same private practice. 7, 20 Analysis was conducted on the entire cohort of NIPT failures.
The normality of maternal age and body mass index (BMI) in the NIPT failure cohort was confirmed using the Shapiro-Wilks test. This was compared with the general Australian obstetric population and the NIPT success cohort using Student's t-tests. The results of antenatal investigation were expressed as multiples of the median (MoM) and were compared with the NIPT success cohort using Mann-Whitney U-tests because normality of these could not be confirmed. The incidence of pregnancy outcomes was compared with the general Australian obstetric population using binomial tests. Separate subgroup analysis was also performed on those women with low fetal fraction and repeat NIPT failures. Statistical analysis was performed using R version 3.3.2.
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Results
Characteristics of study population
A total of 12 033 women underwent NIPT at Sydney Ultrasound For Women during the study period, with 6375 (53%) undertaking Harmony TM tests and 5658 (47%) undertaking GeneSyteâ tests. There were 131 participants who received an inconclusive result (1.1%), of whom 119 (90.8%) were conducted by Harmony TM and 12 (9.2%) by GeneSyteâ. The Harmony TM inconclusive test result percentage at 1.9% (119/6375) was significantly higher than that for GeneSyteâ (0.2%, 12/5658; P < 0.0001; binomial test). Low fetal fraction was reported as the cause of NIPT failure in 59 women (45%) of the cohort, and technical assay failure or logistical issues in 59 women (45%). In 13 women (10%), the reason for failure was not reported.
Women who failed to obtain a result from NIPT had a higher mean BMI when compared with those who received a result (28.5 versus 23.3 kg/m 2 ; P < 0.0001) as well as to the general Australian obstetric population (28.5 versus 26.0 kg/m 2 ; P = 0.0001). They were older than the general Australian obstetric population (35 versus 30 years; P < 0.0001) but younger than those with test success at the same clinical practice (35 versus 36.2 years; P = 0.001). The 59 women who failed to achieve a result due to low fetal fraction had significantly increased BMI (30.8 versus 28.5 kg/m 2 , P = 0.04) compared with the remainder of the cohort. No other significant demographic or pregnancy outcome metrics was found. There was no difference in gestational age at testing between those who failed to achieve a test result and those with test success (11.4 versus 11.3 weeks; P = 0.6).
On review of placental function markers, women with test failure had significantly lower levels of PAPP-A and fbhCG as well as significantly higher uterine artery PI than those with test success, but there was no significant difference in PlGF. The comparisons are detailed in Table 1 . There were no differences in these investigations between those with test failure due to low fetal fraction and those whose tests failed due to technical laboratory issues.
With regards to pregnancy outcomes in the test failure cohort, 85 women (64.9%) had first trimester pre-eclampsia screening. Of those, 13 (15.2%) had a risk greater than 1 in 50, which was higher than found in routine screening of a comparable Sydney obstetric population, but did not reach significance (15.2% versus 9.9%, P = 0.1). 22 Of the high pre-eclampsia risk group, six women (46%) developed pre-eclampsia and three delivered before 34 weeks of gestation.
Screening pathway after NIPT test failure
Of the 131 women who failed to obtain a result, 75 underwent a subsequent sample collection for NIPT either with GeneSyteâ, Harmony TM , Verifi TM or Panorama TM , whereas the remainder pursued alternative screening pathways as detailed in Figure 1 . Of the 75 who underwent a repeat NIPT, 13 (17.3% of all repeat samples; 28.3% of repeat Harmony TM samples) again received an inconclusive result.
Pregnancy outcomes
Despite extensive efforts to contact the women by telephone and post, pregnancy outcomes for eight women (6%) are unknown. There was no significant difference in age, BMI or gestation at NIPT between these eight women and the 123 women for whom outcomes are known. In the final cohort of 123 women, there were 110 live births and 13 cases with adverse pregnancy outcome (10.1% of those with known outcomes and 10.0% of the total cohort). The adverse outcomes included seven terminations of pregnancy (including six cases of chromosome abnormality), five miscarriages (two with chromosomal abnormalities) and one stillbirth. Pregnancy outcomes and relevant clinical information are detailed in Table 2 . There were eight cases of chromosomal aneuploidy in these 123 pregnancies (6.5% of those with known outcomes and 6.1% of the entire cohort), which is significantly higher than the 0.2% rate in the general obstetric population (P < 0.0001). The majority of these involved uncommon aneuploidies and three (38%) of these had low fetal fraction as the reported reason for NIPT failure.
Of the 110 live births, the incidence of pregnancy complications such as pre-eclampsia and GDM was significantly higher than the general obstetric population, whereas there was no significant difference in rates of SGA or preterm delivery (Table 3) . Of the 13 women who repeatedly failed to receive a result from NIPT, there was one case of triploidy resulting in miscarriage. No other chromosomal abnormalities were found in this group. Of the remaining 12 women, the birth outcome is known in 11 cases. Of these, six (55%) were complicated by GDM, one by SGA and one by pre-eclampsia.
There was no significant difference in the incidences of these adverse outcomes between the low fetal fraction group and the group that failed due to technical reasons.
Discussion
Main findings
In this study, we observed that the cohort of women who failed to receive a result from NIPT experienced a significantly increased number of adverse outcomes including late miscarriage, chromosomal abnormality, pre-eclampsia and GDM.
The finding of uncommon chromosomal aneuploidies such as triploidy, trisomy 9 and trisomy 10 in the study cohort reflects an association with smaller placentas which is likely to be responsible for the abnormal cell free fetal DNA (cffDNA) levels and subsequent failure to obtain a result from NIPT. 3 On the other hand, sex chromosome aneuploidy and trisomy 21 were also identified in this cohort, and these are considered unlikely to create abnormal placental volume and on the contrary, enhanced cell turnover is generally considered to create excess cffDNA in trisomy 21.
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With regards to antenatal investigations, PAPP-A and fbhCG were significantly lower in the NIPT failure cohort. Moreover, fbhCG was lower in the group failing due to low fetal fraction compared with those with failures for other reasons. This could be a reflection of poorer placental function and/or decreased placental volume. The increased uterine artery mean PI measurements and decreased PAPP-A are both associated with an increased risk of pre-eclampsia, which correlates with the increased incidence of preeclampsia found in our study cohort. Pre-eclampsia is theorised to develop as a result of impaired invasion by the trophoblasts during early gestation leading to abnormal placentation. 25 It is feasible that this same pathological process might then cause abnormal apoptosis of these trophoblasts, resulting in abnormal amounts of cffDNA being released into the maternal blood that is required for analysis in NIPT. 26 The study cohort had a higher BMI than the general Australian obstetric population. The only significant difference demonstrated between those women who had insufficient fetal fraction and those who did not receive a result from NIPT for other reasons was an increased BMI, which suggests a dilutional effect and increased maternal adipocyte turnover as the principal causes. 12 The increased BMI observed in our cohort may also act as a confounding factor when considering the apparent significant increase in rates of GDM and pre-eclampsia. 27 Callaway reported a correlation between BMI and both GDM and pre-eclampsia (unadjusted odds ratio for BMI between 25 and 29.9 kg/m 2 of 1.78 and 1.74 for GDM and pre-eclampsia, respectively). 28 It was difficult to draw any conclusions regarding those who repeatedly failed to obtain a result due to the small numbers in this particular group.
The overall NIPT failure rate during the study period of 1.1% compares favourably with a recent systematic review of 11 studies reporting failure rates ranging from 0 to 4.9%. 29 As the analysis in NIPT is performed on all cellfree DNA in the sample, a minimum fetal fraction (ranging from 2 to 4% total cell free DNA) is required for the test to have adequate statistical power. However, some NT, nuchal translucency; PPROM, preterm pre-labour rupture of membranes; TOP, termination of pregnancy; UA, uterine artery; NIPT, noninvasive prenatal testing.
commercial laboratories assert that reliable results from NIPT are possible without measuring the amount of fetal fraction. Takoudes and Hamar reported in 2015 on a sample challenge that resulted in nonpregnant women receiving a result from NIPT at some laboratories. 30 In their theoretical study, Wright et al. found the detection rate of a method combining NIPT with combined first-trimester screening test to increase from 62% to 100% as fetal fraction increases from 4% to ≥9%.
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Our study provides further evidence that increased BMI is correlated with decreased fetal fraction, as has been established in previous studies. 13, 23, 26 Furthermore, other studies including that by Ashoor et al. found that fetal fraction also varied depending on ethnicity, although this was not explored in our study. 13 The reported reasons for failure in our study are distributed in a similar fashion to those demonstrated previously with both Benn and Norton and their colleagues reporting that around half of the 'no results' in their studies were attributable to low fetal fraction. 10, 29 Fetal fraction is affected by chromosomal abnormalities, with trisomy 21 having increased fetal fraction while trisomies 13 and 18, monosomy X and triploidy may be associated with lower fetal fraction. 3, 23, 24 We found an increased rate of chromosomal abnormalities (6.5% of the entire cohort) in those who failed to receive a result from NIPT, concurring with previous studies. Norton and Wapner, in their study, reported a significantly elevated aneuploidy rate (2.7%) compared with their overall cohort prevalence (0.4%), 10 as did Pergament et al. 19 , in their study in high-risk patients (23% versus 11%). 32 This is compared with the general obstetric population incidence of 0.2%. As found in the current study, the chromosome abnormalities in these 'no result' cohorts tended to be the rarer aneuploidies, most often associated with small-volume placentae. Gil et al. 33 found in their retrospective study that pregnancies affected by trisomies and sex chromosome aneuploidies had significantly increased rates of NIPT failure (6.9% and 17.2%, respectively).
Although we found an association between NIPT failure and pre-eclampsia, previous studies have focused specifically on fetal fraction and pre-eclampsia. The literature is inconclusive about this with some studies finding an elevation in fetal fraction before disease onset, 8, [34] [35] [36] whereas others report no significant difference between pre-eclamptic and normal cohorts. 37, 38 It is worth noting that the association with pre-eclampsia in our study was present in both our overall cohort and the low fetal fraction cohort, suggesting that there may be pathological processes involved, leading to not only decreased quantity but also other abnormalities in the cffDNA. However, the increased age and BMI in our cohort may account for some of this increase. 27, 39 This study found no significant increase in SGA or preterm birth and, again, the literature is mixed regarding the association of fetal fraction at 10-14 weeks of gestation and these conditions.
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Strengths
The strengths of this study are the large number of NIPT tests conducted by a dedicated screening practice with access to skilled and appropriately trained medical and allied health personnel. There were sufficient test failures to provide robust comparative analysis.
Limitations
Being conducted entirely in private practice, the cohort in this study may not be representative of the whole obstetric community. Moreover, as a private tertiary referral screening centre, decisions regarding patient management are made by the referring clinicians, rather than the screening practice specialists, which accounts for the variability in antenatal investigations performed. The retrospective nature of this cohort study means that there was limited control over data collection, resulting in an incomplete data set: there were eight women (6%) for whom pregnancy outcomes were unknown despite repeated attempts at follow up. This study is also susceptible to recall bias as pregnancy outcomes were self-reported. Using different testing platforms in this study may also lead to a lack of standardisation within the failure cohort.
Interpretation
This study demonstrated that the group of women who failed to receive a result from NIPT were at increased risk for adverse pregnancy outcomes, including chromosome abnormalities and pregnancy complications such as preeclampsia and GDM. Moreover, the failure rate of NIPT indicates that there is still an important role for combined first-trimester ultrasound and biochemical screening and for conventional invasive prenatal testing (chorionic villus sampling, amniocentesis), which rarely fails to report a result and also tests for a larger number of chromosomal and genetic abnormalities.
Conclusion
Failure to achieve a result from NIPT is associated with a higher risk for adverse pregnancy outcome. These women require careful counselling, possible definitive prenatal testing and more stringent antenatal monitoring. A potential future study in this cohort of women may investigate the placenta-maternal immunological interface through exosome testing to provide additional insight into abnormal placental function.
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